INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Key claim: A Phase 1/2 dose-escalation and expansion study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of INCB000928 as monotherapy or combined with ruxolitinib in myelofibrosis patients with transfusion-dependent or symptomatic anemia.
Abstract
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Why this matters
Anemia is a major upstream driver of fatigue in myelofibrosis, and current options (ESAs, danazol, transfusions) are limited in efficacy and durability. INCB000928 expands the growing pipeline of novel anemia-directed agents (luspatercept, elritercept, nelfinavir) being tested both as monotherapy and as add-ons to ruxolitinib, potentially decoupling JAK inhibitor–associated cytopenias from symptom control. Early-phase status means efficacy data on transfusion independence and symptom burden are still pending.